Research programme: respiratory disease therapeutics - Almirall/Evotec
Latest Information Update: 27 Sep 2010
At a glance
- Originator Almirall S.A.; Evotec AG
- Class Small molecules
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Respiration disorders
Most Recent Events
- 23 Sep 2010 Investigation in Respiration disorders in Germany (unspecified route)